All News
Filter News
Found 2,520 articles
-
Flagship Pioneering Unveils Cygnal Therapeutics
10/8/2019
Company is Developing Drugs in the Field of Exoneural Biology to Address Cancer, Inflammatory Disease, and More [08-October-2019] CAMBRIDGE, Mass. , Oct. 8, 2019 /PRNewswire/ -- Flagship Pioneering, a unique life sciences innovation enterprise, today unveiled Cygnal Therapeutics . Founded in 2017 in Flagship Labs, Flagship's innovation foundry, Cygnal is the first co
-
Moderna to Present Data From Two of Its Prophylactic mRNA Vaccines at IDWeek 2019
10/2/2019
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced data presentations regarding two of its wholly owned prophylactic mRNA vaccines at IDWeek in Washington, D.C.
-
Torque Therapeutics Announces the Appointment of John Cox as Chief Executive Officer
10/2/2019
Torque Therapeutics, a clinical stage, product-platform company developing proprietary, first-in-class Deep Primed™ adoptive cell transfer therapeutics with uniquely broad potential to treat patients with a wide range of hematologic and solid malignancies, announced the appointment of John Cox as Chief Executive Officer.
-
Vor Biopharma Hires Senior Cell and Gene Therapy Leaders as Chief Technology Officer and Vice President of Research
10/1/2019
Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells for the treatment of cancer, announced senior appointments to its leadership team.
-
Moderna Announces Open IND for Propionic Acidemia Program (mRNA-3927)
9/30/2019
Moderna, Inc. announced the U.S. Food and Drug Administration has completed their review of the Investigational New Drug application for mRNA-3927, its investigational mRNA therapeutic for propionic acidemia and allowed it to proceed to clinic.
-
Harvard University Establishes mRna Immunotherapy Research Collaboration With Moderna
9/26/2019
Harvard University has established a multi-year research collaboration with the biotech company Moderna, Inc., with the goal of identifying and developing novel therapeutic approaches that could improve the lives of patients with immunological diseases
-
Moderna Announces mRNA Immunotherapy Research Collaboration with Harvard University
9/26/2019
Collaboration seeks to explore fundamental immunological processes and identify potential therapeutic opportunities
-
Moderna to Present at Upcoming Investor Conferences in October 2019
9/25/2019
Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines to create a new generation of transformative medicines for patients, announced its participation in the following upcoming investor conferences
-
Flagship Pioneering Unveils Omega Therapeutics and Appoints Seasoned BioPharma Executive Mahesh Karande as President and Chief Executive Officer
9/23/2019
Omega Therapeutics is unleashing the human genome’s native capacity to regulate genes and cure disease for a new era of genomic medicine
-
Goodwin Welcomes Life Sciences Licensing and Collaboration Partner Lily Wound in New York
9/12/2019
Global law firm Goodwin announced today that Lily Wound has joined its Technology and Life Sciences practices as a partner in the New York office.
-
Moderna Announces Positive Phase 1 Results for the First Systemic Messenger RNA Therapeutic Encoding a Secreted Protein (mRNA-1944)
9/12/2019
Moderna, Inc. announced positive data in the first analysis of safety and activity in its Phase 1 study evaluating escalating doses of mRNA-1944 administered via intravenous infusion in healthy adults.
-
Moderna Announces Positive Interim Results from Phase 1 Cytomegalovirus (CMV) Vaccine (mRNA-1647) Study and Progress Toward Phase 2 and Pivotal Trials
9/12/2019
Moderna, Inc. announced positive data from the three-month interim analysis of safety and immunogenicity of the Phase 1 study of its investigational cytomegalovirus vaccine.
-
Trucode’s triplex gene-editing technology uses proprietary synthetic peptide nucleic acid oligomers and DNA correction sequences to edit disease-causing mutations by harnessing natural DNA repair mechanisms.
-
Trucode Launched to Advance Next-Generation Gene Editing Platform
9/10/2019
Translating novel triplex gene editing technology for patients with genetic disorders
-
BioSpace Movers & Shakers, Sept. 6
9/6/2019
Biopharma companies strengthen the C-suite and board of directors with these appointments. -
Moderna Appoints Tracey Franklin as Chief Human Resources Officer
9/4/2019
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Tracey Franklin has been appointed Chief Human Resources Officer
-
Moderna to Host R&D Day on September 12, 2019
8/29/2019
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will host its third annual R&D Day for analysts and investors at 8:00 a.m. ET on Thursday, September 12 at the JW Marriott Essex House in New York City.
-
Wouldn’t it be amazing to be able to see a protein being made in a cell in real time? And wouldn’t it be even better if you could use that capability to discover new drugs to previously “undruggable” targets, creating new medicines? Well that’s exactly what Anima Biotech is aiming to do.
-
Moderna to Present at Upcoming Investor Conferences
8/27/2019
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced its participation in the following upcoming investor conferences
-
Frequency Therapeutics Expands Leadership Team
8/22/2019
Frequency Therapeutics, Inc., a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced new appointments to its leadership team.